Terms: = Prostate cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Treatment
37 results:
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
2. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
3. Mismatch repair gene germline mutations in patients with prostate cancer.
Fang B; Wei Y; Pan J; Zhang T; Ye D; Zhu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):133-138. PubMed ID: 37283096
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome Sequencing of Nigerian prostate Tumors from the prostate cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Martin DN; Yates C
Cancer Res Commun; 2022 Sep; 2(9):1005-1016. PubMed ID: 36922933
[TBL] [Abstract] [Full Text] [Related]
5. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with prostate cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
7. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract] [Full Text] [Related]
8. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract] [Full Text] [Related]
9. Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade.
Sena LA; Salles DC; Engle EL; Zhu Q; Tukachinsky H; Lotan TL; Antonarakis ES
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34140335
[TBL] [Abstract] [Full Text] [Related]
10. [A Case of Metachronous Quintuple cancer Involving the Stomach, Rectum, Colon, Liver and prostate].
Kihara Y; Takeda Y; Ohmura Y; Katsura Y; Sakamoto T; Shinke G; Taguchi I; Nagano T; Kawai K; Kitahara T; Hiraki M; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Apr; 48(4):608-611. PubMed ID: 33976064
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of a Mainstream Model of Genetic Testing for Men With prostate cancer.
Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG
JCO Oncol Pract; 2021 Feb; 17(2):e204-e216. PubMed ID: 32970524
[TBL] [Abstract] [Full Text] [Related]
12. Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Zhai B; Li Y; Kotapalli SS; Bacha J; Brown D; Steinø A; Daugaard M
Cell Death Dis; 2020 Jul; 11(7):577. PubMed ID: 32709853
[TBL] [Abstract] [Full Text] [Related]
13. Hereditary Predisposition to prostate cancer: From Genetics to Clinical Implications.
Brandão A; Paulo P; Teixeira MR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
[TBL] [Abstract] [Full Text] [Related]
14. The impact of TP53BP1 and mlh1 on metastatic capability in cases of locally advanced prostate cancer and their usefulness in clinical practice.
Gzil A; Jaworski D; Antosik P; Zarębska I; Durślewicz J; Dominiak J; Kasperska A; Neska-Długosz I; Grzanka D; Szylberg Ł
Urol Oncol; 2020 Jun; 38(6):600.e17-600.e26. PubMed ID: 32280038
[TBL] [Abstract] [Full Text] [Related]
15. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract] [Full Text] [Related]
16. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract] [Full Text] [Related]
17. Germline and Somatic Mutations in prostate cancer for the Clinician.
Cheng HH; Sokolova AO; Schaeffer EM; Small EJ; Higano CS
J Natl Compr Canc Netw; 2019 May; 17(5):515-521. PubMed ID: 31085765
[TBL] [Abstract] [Full Text] [Related]
18. Bringing prostate cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract] [Full Text] [Related]
19. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract] [Full Text] [Related]
20. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous prostate cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Liu W; Zhang D; Tan SA; Liu X; Lai J
Anticancer Res; 2018 Aug; 38(8):4847-4852. PubMed ID: 30061258
[TBL] [Abstract] [Full Text] [Related]
[Next]
